Roche�s $RHHBY Q3 revenue rose 4.5% to 12.48 billion Swiss francs (12.6b). The topline fell a tad short of the company forecast, which was for 12.55b francs. Sales were lifted by the strong performance of the company�s cancer and immunotherapy treatments. It included Roche�s trio of drugs for treating the HER2-positive form of breast cancer, Gazya for chronic lymphocytic leukemia, Acterma for rheumatoid arthritis, and Esbriet for the lung disease idiopathic pulmonary fibrosis. The drug-makers overall pharmaceutical sales rose to 9.68b from 9.34b francs. Diagnostic unit�s revenue rose to 2.8b francs from 2.6b francs. The company maintained FY sales to grow at a low-to-mid single-digit range at constant exchange rate.